Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

被引：11
|
作者：
Angelini, Silvia [1 ,2 ]
Botticelli, Andrea [1 ]
Onesti, Concetta Elisa [1 ,2 ]
Giusti, Raffaele [2 ]
Sini, Valentina [1 ,3 ]
Durante, Valeria [1 ,2 ]
Strigari, Lidia [4 ]
Gentile, Giovanna [5 ]
Cerbelli, Bruna [6 ]
Pellegrini, Patrizia [2 ]
Sgroi, Valentina [1 ,2 ]
Occhipinti, Mario [1 ,2 ]
Di Pietro, Francesca Romana [1 ,2 ]
Rossi, Alessandro [7 ]
Simmaco, Maurizio [8 ]
Mazzuca, Federica [1 ,2 ]
Marchetti, Paolo [1 ,2 ,5 ]
机构：
[1] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy
[2] St Andrea Hosp, Dept Med Oncol, Via Grottarossa 1035, I-00189 Rome, Italy
[3] Santo Spirito Hosp, Rome, Italy
[4] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Rome, Italy
[5] Immacolata IDI IRCSS, Dermopat Inst, Rome, Italy
[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
[7] Sapienza Univ Rome, Fac Med & Psychol, Rome, Italy
[8] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, Rome, Italy
来源：
ANTICANCER RESEARCH | 2017年 / 37卷 / 05期
关键词：
Breast cancer; taxanes; polymorphisms; ABCB1; P-gp; cytochrome P450; GENETIC POLYMORPHISMS; PERIPHERAL NEUROPATHY; RANDOMIZED-TRIAL; OVARIAN-CANCER; HUMAN LIVER; PACLITAXEL; ABCB1; DOCETAXEL; EXPRESSION; CHEMOTHERAPY;
D O I：
10.21873/anticanres.11610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Taxanes are widely used to treat breast cancer patients. Taxanes are metabolized in human liver by the cytochrome CYP3A and are substrate of ATP-binding cassette multidrug transporters ABCB1. Single-nucleotide polymorphisms (SNPs) in genes involved in taxanes' metabolism could affect the inter-individual variability in reported toxicities. Materials and Methods: In this retrospective study, 152 women, affected by breast cancer and receiving a taxane-based chemotherapy, were enrolled. A peripheral blood sample was taken for genotyping the following polymorphisms: CYP3A4* 1B (A>G), CYP3A5 * 3 (G>A) and ABCB1 (C1236T; C3435T). Results: We observed an association between ABCB1 3435 T/T and lower grade of toxicities (p=0.05). No other association were found for CYP 3A4 * 1B, 3A5*3 and ABCB1 C1236T. Conclusion: ABCB1 3435 T/T seems to be associated to lower rate of toxicity in patients receiving taxanes. Further prospective and larger studies should be performed to clarify the role of this polymorphism.
引用
收藏
页码：2633 / 2639
页数：7
相关论文
共 50 条
  • [1] Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity
    Lerzo, GL
    Temperley, G
    Rosales, C
    Campos, C
    Lezcano, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S74
  • [2] ACUTE TOXICITY IN PATIENTS TREATED POSTOPERATIVELY WITH CONCURRENT RADIOTHERAPY AND TAXANES FOR BREAST CANCER. A RETROSPECTIVE ANALYSIS
    Huscher, A.
    Simoncini, E.
    Montani, E.
    Barbieri, D.
    Bandera, L.
    Amoroso, V.
    Lazzari, B.
    Pietta, G.
    Maddalo, M.
    Pedretti, S.
    Frata, P.
    Magrini, S.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S293 - S293
  • [3] Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach
    Tulsyan, Sonam
    Chaturvedi, Pankaj
    Singh, Abhishek Kumar
    Agarwal, Gaurav
    Lal, Punita
    Agrawal, Sushma
    Mittal, Rama Devi
    Mittal, Balraj
    GENE, 2014, 543 (01) : 69 - 75
  • [4] A pharmacogenetic analysis of peripheral sensory neuropathy related to administration of taxanes in breast cancer patients.
    Leonard, Alyson
    Gudena, Vinay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Taxanes in elderly breast cancer patients
    Wildiers, H
    Paridaens, R
    CANCER TREATMENT REVIEWS, 2004, 30 (04) : 333 - 342
  • [6] Risk of radiation pneumonitis in breast cancer patients treated with adjuvant taxanes and radiation.
    Voduc, KD
    Tyldesley, S
    Chia, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 33S - 33S
  • [7] Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Schmid, P
    Schippinger, V
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Freier, W
    Van de Velde, H
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S68 - S69
  • [8] Pharmacogenetic Assessment of Toxicity After Docetaxel Chemotherapy In Breast Cancer
    De Lulijs, F.
    Russo, I.
    Di Trapani, M. C.
    Gentile, G.
    Sgroi, V.
    Roselli, A.
    Trasatti, L.
    Pellegrini, P.
    Simmaco, M.
    Marchetti, P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S179 - S179
  • [9] Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Benekli, Mustafa
    Yildiz, Ramazan
    Uner, Aytug
    Er, Ozlem
    Yamac, Deniz
    Alkis, Necati
    Coskun, Ugur
    Camci, Celalettin
    Buyukberber, Suleyman
    ONCOLOGY, 2007, 72 (5-6) : 308 - 313
  • [10] Cardio toxicity for older breast cancer patients treated with trastuzumab
    Bensalem, A.
    Hamdouche, R.
    Bensehamdi, A.
    Boudersa, A.
    Yousfi, N.
    Bouzid, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S343 - S343
12345